You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

88 Results
Guidelines and Advice
Status: Archived
ID: CED 15
Nov 2009
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    idelalisib - For the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, according to specific clinical criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) - In Combination with Idelalisib - Relapsed Chronic Lymphocytic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
idelalisib,
riTUXimab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2023
Drug
Other Name(s): Gazyva®
Quick Link(s):
Drug Monograph, Patient Info Sheet
May 2022
Drug
Other Name(s): Zydelig™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2022
Drug
Other Name(s): Brukinsa®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2024
Guidelines and Advice
Status: Archived
ID: 6-8
Version: 3
Mar 2015
Drug
Other Name(s): Venclexta®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Aug 2025
Drug
Other Name(s): Treanda®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Imbruvica®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL), 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - Non-Hodgkin's Low Grade, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    cyclophosphamide - oral tablets
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Drug
Other Name(s): Fludara®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL), 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    chlorambucil
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
chlorambucil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019

Pages